Inhaled, Fast-acting Antibody Treatments for Acute Respiratory Infections

 Inhalon Biopharma is a clinical-stage biotechnology company

with a precedent-setting inhaled drug platform for treating patients suffering from acute respiratory infections, such as respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza, and SARS-CoV-2.  

With the goal of providing superior effectiveness and at-home convenience, Inhalon is developing a pipeline of proprietary inhaled antibody treatments that enables a simplified “test-to-treat” model as a new standard of respiratory care.